Stockscreener 앱 받기
3.01
4.44%
-0.14
시간 외 거래:
3.11
0.10
+3.32%
Macrogenics Inc 주식(MGNX)의 최신 뉴스
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MacroGenics expands royalty deal with Sagard for $60M By Investing.com - Investing.com South Africa
MacroGenics (MGNX) price target increased by 50.00% to 6.12 - MSN
MacroGenics Expands ZYNYZ Royalty Agreement for Added Funding - TipRanks
MacroGenics (Nasdaq: MGNX) secures $60M in expanded ZYNYZ royalty deal - Stock Titan
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
MacroGenics expands royalty deal with Sagard for $60M - Investing.com UK
MacroGenics Expands ZYNYZ Royalty Deal With Sagard Healthcare Partners - Moomoo
Macrogenics and Sagard Healthcare Partners enter into expanded Zynyz® Royalty Purchase Agreement - marketscreener.com
$60M now, up to $20M more: MacroGenics expands ZYNYZ deal - Stock Titan
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement - Yahoo Finance
MSN Money - MSN
MSN - MSN
MacroGenics, Inc. (NASDAQ:MGNX) Short Interest Down 22.5% in April - MarketBeat
MacroGenics gains removal of FDA partial hold on lead program - MSN
MacroGenics (MGNX) price target increased by 11.11% to 4.08 - MSN
B Riley Securities upgrades MacroGenics (MGNX) - MSN
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
MacroGenics (MGNX) Stock Research | Q4 2025: EPS Beats ForecastsROIC - Cổng thông tin điện tử tỉnh Lào Cai
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MGNX Maintains by Barclays -- Price Target Raised to $6.00 - GuruFocus
Macrogenics Is Maintained at Overweight by Barclays - Moomoo
MacroGenics Inc stock (US5562221046): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
MacroGenics Nears Key Prostate Cancer Catalyst as Phase 2 Lorigerlimab Trial Completes - TipRanks
FDA Lifts Clinical Hold on MacroGenics Phase 2 Cancer Trial - HarianBasis.co
B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity - Yahoo Finance
MacroGenics (MGNX) Stock: Stabilizing? (Smart Money Outflows) 2026-04-16High Volume Stocks - Cổng thông tin điện tử tỉnh Lào Cai
MacroGenics (MGNX) Stock Take Profit (Momentum Building) 2026-04-15Global Trading Community - Cổng thông tin điện tử tỉnh Tây Ninh
Recap Report: What is the next catalyst for MacroGenics IncQuarterly Profit Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Sentiment Review: Whats the profit margin of MacroGenics Inc2026 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley Securities | MGNX Stock News - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley - GuruFocus
Macrogenics Inc Stock Historical Valuations | HAM:M55 - GuruFocus
Macrogenics Inc Stock Intrinsic Values | HAM:M55 - GuruFocus
1.77%
0.25%
자본화:
|
볼륨(24시간):